Recurrence Timing and Risk Following Curative Resection of Colorectal Liver Metastases: Insights From a Hazard Function Analysis
Journal of Surgical Oncology · 2025-04 · 131 (5) · 857-864
DOI: 10.1002/jso.28007 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Surgical Oncology, online erschienen am 21.11.2024. Verfasst von Jun Kawashima und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Neoplasm Recurrence, Local, Hepatectomy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Introduction
There is no consensus on the optimal surveillance interval for patients undergoing resection of colorectal liver metastases (CRLM). We sought to assess the timing and intensity of recurrence following curative‐intent resection of CRLM utilizing a recurrence‐free survival (RFS) hazard function analysis.
Methods
Patients with CRLM who underwent curative‐intent resection were identified from a multi‐institutional database. The RFS hazard function was used to plot hazard rates and identify the peak of recurrence over time.
Results
Among 1804 patients, the median RFS was 19.9 months. In the analytic cohort, the RFS hazard curve peaked at 5.9 months (peak hazard rate: 0.054) and gradually declined, indicative of early recurrence. In subgroup analyses, patients with high and medium tumor burden scores (TBS) had RFS hazard peaks at 4.9 months (peak hazard rate: 0.060) and 5.8 months (peak hazard rate: 0.054), respectively. In contrast, patients with low TBS had a later peak at 7.5 months, with the lowest peak hazard rate of 0.047.
Conclusions
The recurrence peak for CRLM patients occurred approximately 6 months postsurgery, highlighting the need for intensified early postoperative surveillance. Patients with high TBS experienced earlier recurrence, underscoring the importance of close monitoring, particularly during the first 6 months after surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.
- Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
- Department of Transplant Surgery, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Surgery, University of Verona, Verona, Italy.
- Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
- Department of Surgery, Keio University, Tokyo, Japan.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Kawashima, J., Akabane, M., Endo, Y., Woldesenbet, S., Altaf, A., Ruzzenente, A., Popescu, I., Kitago, M., Poultsides, G., Sasaki, K., Aucejo, F., Sahara, K., Endo, I., & Pawlik, T. M. (2025). Recurrence Timing and Risk Following Curative Resection of Colorectal Liver Metastases: Insights From a Hazard Function Analysis. Journal of Surgical Oncology, 131(5), 857-864. https://doi.org/10.1002/jso.28007
Vancouver
Kawashima J, Akabane M, Endo Y, Woldesenbet S, Altaf A, Ruzzenente A, et al. Recurrence Timing and Risk Following Curative Resection of Colorectal Liver Metastases: Insights From a Hazard Function Analysis. Journal of Surgical Oncology. 2025;131(5):857-864. doi:10.1002/jso.28007
BibTeX
@article{Kawashima2025,
author = {Kawashima, Jun and Akabane, Miho and Endo, Yutaka and Woldesenbet, Selamawit and Altaf, Abdullah and Ruzzenente, Andrea and Popescu, Irinel and Kitago, Minoru and Poultsides, George and Sasaki, Kazunari and Aucejo, Federico and Sahara, Kota and Endo, Itaru and Pawlik, Timothy M},
title = {Recurrence Timing and Risk Following Curative Resection of Colorectal Liver Metastases: Insights From a Hazard Function Analysis},
journal = {Journal of Surgical Oncology},
year = {2025},
volume = {131},
number = {5},
pages = {857--864},
doi = {10.1002/jso.28007}
}
EUVIMED